Press Releases
Sep 22, 2023
PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) Significantly Improve Overall Survival and Progression-Free Survival in Patients With Previously Untreated Advanced Bladder Cancer in Pivotal Phase 3 EV-302 Trial

– Trial results to be submitted for presentation at upcoming medical meeting – TOKYO and BOTHELL, Wash., Sept. 22, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE:4503, President and CEO: Naoki...

Sep 20, 2023
Two-time Emmy® Award-Winning Actor, Eric Stonestreet, Partners with Iveric Bio to Raise Awareness of Geographic Atrophy (GA)

GA is a form of age-related macular degeneration (AMD) that causes irreversible vision loss, affecting approximately 1.5 million people in the United States1,2 Eric and his mother, Jamey, are...

Sep 18, 2023
Iveric Bio Announces Positive 24-Month Topline Results from Phase 3 Study of IZERVAY™ (avacincaptad pegol intravitreal solution) for Geographic Atrophy

GATHER2 24-month results met the primary objective of reducing the rate of GA growth in patients treated with IZERVAY compared to sham IZERVAY 24-month safety data were consistent with 12-month...

EXPLORE ALL US PRESS RELEASES

Articles
Oct 2, 2023
Astellas Celebrates Global Diversity Awareness Month – Honoring our Commitment to Expanding and Evolving EDEI Globally

Astellas reflects on the importance of engagement, diversity, equity and inclusion in fostering a people-centric culture. Astellas is proud to celebrate Global Diversity Awareness Month this...

Jul 11, 2023
Astellas Scores 100 Again on Disability Equality Index for Fourth Consecutive Year

Our consistent top score demonstrates our continuing effort to create an inclusive culture for people with disabilities. For the fourth year in a row, Astellas has been included in the Disability...

May 5, 2023
Astellas Pledges to End Cancer Stigma in the Workplace

As a global pharmaceutical company, Astellas takes the fight against cancer personally and is deeply committed to our employees and customers who are a part of the oncology community. Fifty...

EXPLORE ALL ARTICLES

Stay Connected

Get only the email alerts you want.

Subscribe

Media Contacts

 

For media inquiries and reporter requests, please click here to fill out a request form.

Our communications team will respond to verified media requests within 24-48 hours as appropriate.

If you are not a reporter and need assistance, please visit our contact us page that includes information for patients, healthcare providers and researchers.

 

Astellas on Twitter
Download Fact Sheet

Download Fact Sheet

Sustainability

Sustainability

Investors

Investors

Explore U.S. Products

Explore U.S. Products